Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KAI Research (KAI), a wholly owned subsidiary of Altarum Institute, announced today that the Centers for Disease Control and Prevention (CDC) awarded it a contract to evaluate samples of pediatric, adult, and elderly individuals’ serum levels after flu vaccination to determine whether antibodies induced by the current vaccine effectively inhibit circulating influenza viruses.
Subscribe to our email newsletter
This project is part of CDC’s surveillance effort, with the potential to continue up to 5 years.
KAI is a full-service Contract Research Organization providing support to both government and commercial clients, including protocol review, regulatory tracking, monitoring, site management, safety monitoring, pharmacovigilance, data management, and statistical analysis support.
To support this initiative, KAI has developed a strategic partnership with Benchmark Research, a geographically diverse, integrated site network composed of six dedicated, multitherapeutic research centers that specialize in vaccine research.
"We are excited to collaborate with KAI on this important initiative in support of the CDC’s valuable work on flu surveillance," said Mark Lacy, CEO of Benchmark Research.
"This effort aligns well with our strong emphasis on delivering excellence in vaccine research."
"KAI is proud to engage in this critical work with the CDC and establish this collaboration with Benchmark," said KAI President Kathy Dimeo.
"The award of this contract allows us to continue to build strong and meaningful partnerships with the U.S. Government, industry, and academia."